Top Markets
Coin of the day
Poniard Pharmaceuticals, Inc. Poniard Pharmaceuticals, Inc.

Poniard Pharmaceuticals, Inc.

PARD
Clasificación en acciones #42764
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the... Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
Precio por acción
$0.0001
Última sincronización: 2026-08-11
Capitalización bursátil
$150.00
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Poniard Pharmaceuticals, Inc. (PARD)

Categoría

EPS de Poniard Pharmaceuticals, Inc. (PARD)
EPS a fecha de 2026 TTM: 0
Según los últimos informes financieros y el precio de las acciones de Poniard Pharmaceuticals, Inc., el EPS actual de la empresa (TTM) es 0. Al final del año 2026, la empresa tenía un EPS de 0 igual a al EPS de 2026, que fue de 0.
Historial de EPS de Poniard Pharmaceuticals, Inc. desde 2026 hasta 2026
EPS al final de cada año
Año EPS Cambiar
Not enough data for the provided dates.
EPS de empresas similares o competidoras
Empresa EPS Diferencia de EPS País
$17.32 -
US
$27.74 -
NL
- -
CH
$13.70 -
BE
- -
KR